Cancer diagnosis in people with severe mental illness: Practical and ethical issues

The Lancet Oncology

Volumn 11, Issue 8, 2010, Pages 797-804

  Howard, Louise M ^a   Barley, Elizabeth A ^a   Davies, Elizabeth ^a   Rigg, Anne ^b   Lempp, Heidi ^c   Rose, Diana ^a   Taylor, David ^a   Thornicroft, Graham ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBAMAZEPINE; CLOMIPRAMINE; CLOZAPINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DULOXETINE; ESTROGEN; FLUOXETINE; HALOPERIDOL; LAPATINIB; METOCLOPRAMIDE; NEUROLEPTIC AGENT; PACLITAXEL; PAROXETINE; PHENOTHIAZINE DERIVATIVE; PROGESTERONE; PROSTATE SPECIFIC ANTIGEN; PSYCHOTROPIC AGENT; RECOMBINANT GROWTH FACTOR; RISPERIDONE; SERTRALINE; TAMOXIFEN;

AGRANULOCYTOSIS; ANTIGEN DETECTION; BLOOD DYSCRASIA; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COMORBIDITY; DIGITAL RECTAL EXAMINATION; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERPROLACTINEMIA; LIFESTYLE; LUNG CANCER; MAMMOGRAPHY; MANIC DEPRESSIVE PSYCHOSIS; MELANOMA; MENTAL DISEASE; MENTAL HEALTH SERVICE; MOOD DISORDER; MOTOR DYSFUNCTION; NEUTROPENIA; PHARMACODYNAMICS; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOSIS; QT PROLONGATION; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIGMOIDOSCOPY;

ANTINEOPLASTIC AGENTS; BIPOLAR DISORDER; COMORBIDITY; DRUG INTERACTIONS; HEALTH SERVICES ACCESSIBILITY; HEALTH STATUS DISPARITIES; HUMANS; MASS SCREENING; MENTAL COMPETENCY; MENTAL DISORDERS; NEOPLASMS; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA;

EID: 77955275304     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70085-1     Document Type: Review

References (79)

1. Ruggeri M, Leese M, Thornicroft G, Bisoffi G, Tansella M Definition and prevalence of severe and persistant mental illness. Br J Psychiatry 2000, 177:149-155.
2. International Classification of Diseases (ICD-10): version 2007 WHO, (accessed Nov 10, 2009). http://apps.who.int/classifications/apps/icd/icd10online/.
3. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007, 116:317-333.
4. Mortensen PB, Juel K Mortality and causes of death in schizophrenic patients in Denmark. Acta Psychiatr Scand 1990, 81:372-377.
5. Saha S, Chant D, McGrath J A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry 2007, 64:1123-1131.
6. Brown S, Barraclough B, Inskip H Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000, 177:212-217.
7. Catts VS, Catts SV, O'Toole BI, Frost AD Cancer incidence in patients with schizophrenia and their first-degree relatives-a meta-analysis. Acta Psychiatr Scand 2008, 117:323-336.
8. McCreadie RG Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study. Br J Psychiatry 2002, 181:321-325. Scottish Comorbidity Study Group.
9. Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lonnqvist J Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry 2001, 58:573-578.
10. Howard LM, Leese M, Kumar C, Thornicroft G The general fertility rate in women with psychotic disorders. Am J Psychiatry 2002, 159:991-997.
11. Harvey PW, Everett DJ, Springall CJ Adverse effects of prolactin in rodents and humans: breast and prostate cancer. J Psychopharmacol 2008, 22:20-27.
12. Mortensen PB The occurrence of cancer in first admitted schizophrenic patients. Schizophr Res 1994, 12:185-194.
13. Bergmann JB, Sigurdsson JA, Sigurdsson K What attendance rate can be achieved for Pap smear screening? A case-control study of the characteristics of non-attenders and results of reminder efforts. Scand J Prim Health Care 1996, 14:152-158.
14. Carney CP, Jones LE The influence of type and severity of mental illness on receipt of screening mammography. J Gen Intern Med 2006, 21:1097-1104.
15. Druss BG, Rosenheck RA, Desai MM, Perlin JB Quality of preventive medical care for patients with mental disorders. Med Care 2002, 40:129-136.
16. Lindamer LA, Buse DC, Auslander L, Unutzer J, Bartels SJ, Jeste DV A comparison of gynecological variables and service use among older women with and without schizophrenia. Psychiatr Serv 2003, 54:902-904.
17. Lindamer LA, Wear E, Sadler GR Mammography stages of change in middle-aged women with schizophrenia: an exploratory analysis. BMC Psychiatry 2006, 6:49.
18. Martens PJ, Chochinov HM, Prior HJ, Fransoo R, Burland E Are cervical cancer screening rates different for women with schizophrenia? A Manitoba population-based study. Schizophr Res 2009, 113:101-106.
19. Dickerson FB, McNary SW, Brown CH, Kreyenguhl J, Goldberg RW, Dixon LB Somatic healthcare utilization amongst adults with serious mental illness who are receiving community psychiatric services. Med Care 2003, 41:560-570.
20. Friedman LC, Puryear LJ, Moore A, Green CE Breast and colorectal screening amongst low-income women with psychiatric disorders. Psycho-Oncology 2005, 14:786-791.
21. Lasser KE, Zeytinoglu H, Miller E, Becker AE, Hermann RC, Bor DH Do women who screen positive for mental health disorders in primary care have lower mammography rates?. Gen Hosp Psychiatry 2003, 25:214-216.
22. Owen C, Jessie D, De Vries Robbe M Barriers to cancer screening amongst women with mental health problems. Health Care Women Int 2002, 23:561-566.
23. Steiner JL, Hoff RA, Moffett C, Reynolds H, Mitchell M Preventative healthcare for mentally ill women. Psychiatr Serv 1998, 49:696-698.
24. Werneke U, Horn O, Maryon-Davis A, Wessely S, Donnan S, McPherson K Uptake of screening for breast cancer in patients with mental health problems. J Epidemiol Community Health 2006, 60:600-605.
25. Miller E, Lasser KE, Becker AE Breast and cervical cancer screening for women with mental illness: patient and provider perspectives on improving linkages between primary care and mental health. Arch Womens Ment Health 2007, 10:189-197.
26. Thornicroft G Shunned: Discrimination against People with Mental Illness 2006, Oxford University Press, Oxford.
27. Shipman C, Gysels M, White P, Worth A, Murray SA, Barclay S Improving generalist end of life care: national consultation with practitioners, commissioners, academics, and service user groups. BMJ 2008, 337:720.
28. Druss BG Mental health parity, access, and quality of care. Med Care 2006, 44:497-498.
29. Inagaki T, Yasukawa R, Okazaki S, et al. Factors disturbing treatment for cancer in patients with schizophrenia. Psychiatry Clin Neurosci 2006, 60:327-331.
30. O'Rourke RW, Diggs BS, Spight DH, et al. Psychiatric illness delays diagnosis of esophageal cancer. Dis Esophagus 2008, 21:416-421.
31. Nosarti C, Crayford T, Roberts JV, Elias E, McKenzie K Delay in presentation of symptomatic referrals to a breast clinic: patient and system factors. Br J Cancer 2000, 82:742-748.
32. Jones S, Howard L, Thornicroft G Diagnostic overshadowing: worse physical health care for people with mental illness. Acta Psychiatr Scand 2008, 118:169-171.
33. Equal treatment: closing the gap. A formal investigation into physical health inequalities experienced by people with learning disabilities and/or mental health problems 2006, Disability Rights Commission, Disability Rights Commission, London.
34. Benros ME, Laursen TM, Dalton SO, Mortensen PB Psychiatric disorder as a first manifestation of cancer: a 10-year population-based study. Int J Cancer 2009, 124:2917-2922.
35. Hanson LC, Danis M, Mutran E, Keenan NL Impact of patient incompetence on decisions to use or withhold life-sustaining treatment. Am J Med 1994, 97:235-241.
36. Lawrence D, Jablensky A, Threlfall T, Fuller SA Excess cancer mortality in Western Australia psychiatric patients due to higher case fatality rates. Acta Psychiatr Scand 2000, 101:382-388.
37. Kisely S, Sadek J, MacKenzie A, Lawrence D, Campbell LA Excess cancer mortality in psychiatric patients. Can J Psychiatry 2008, 53:753-761.
38. Tran E, Rouillon F, Loze JY, et al. Cancer mortality in patients with schizophrenia: an 11-year prospective cohort study. Cancer 2009, 115:3555-3562.
39. Saku M, Tokudome S, Ikeda M, et al. Mortality in psychiatric patients, with a specific focus on cancer mortality associated with schizophrenia. Int J Epidemiol 1995, 24:366-372.
40. Levinson MC, Druss BG, Dombrowski EA, Rosenheck RA Barriers to primary medical care among patients at a community mental health center. Psychiatr Serv 2003, 54:1158-1160.
41. Mitchell AJ, Malone D, Doebbeling C Carney Quality of medical care for people with and without comorbid mental illness and substance misuse: systemematic review of comparitive studies. Br J Psychiatry 2009, 194:491-499.
42. Bresee LC, Majumdar SR, Patten SB, Johnson JA Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res 2010, 117:75-82.
43. Filik R, Sipos A, Kehoe PG, et al. The cardiovascular and respiratory health of people with schizophrenia. Acta Psychiatr Scand 2006, 113:298-305.
44. Compton MT, Daumit GL, Druss BG Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: a preventive perspective. Harv Rev Psychiatry 2006, 14:212-222.
45. McCreadie R, Macdonald E, Blacklock C, et al. Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study. BMJ 1998, 317:784-785.
46. Kudoh A Perioperative management for chronic schizophrenic patients. Anesth Analg 2005, 101:1867-1872.
47. Yap KY, Tay WL, Chui WK, Chan A Clinically relevant drug interactions between anticancer drugs and psychotropic agents. Eur J Cancer Care 2009, published online Dec 17. 10.1111/j.1365-2354.2009.01113.x.
48. Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva I Clozapine and agranulocytosis. Lancet 1975, 306:611.
49. Burckart GJ, Snidow J, Bruce W Neutropenia following acute chlorpromazine ingestion. Clin Toxicol 1981, 18:797-801.
50. Grohmann R, Schmidt LG, Spiess-Kiefer C, Ruther E Agranulocytosis and significant leucopenia with neuroleptic drugs: results from the AMUP program. Psychopharmacology 1989, 99(suppl):109-112.
51. Stubner S, Grohmann R, Engel R, et al. Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 2004, 37(suppl 1):70-78.
52. Montgomery SA Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995, 10(suppl 4):37-45.
53. Kasper S, Praschak-Rieder N, Tauscher J, Wolf R A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf 1997, 17:251-264.
54. Frieri T, Barzega G, Bada A, Villari V Maintaining clozapine treatment during chemotherapy for non-Hodgkin's lymphoma. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1611-1612.
55. Goulet K, Grignon S Case report: clozapine given in the context of chemotherapy for lung cancer. Psychooncology 2008, 17:512-516.
56. Crawford J, Althaus B, Armitage J, et al. Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007, 5:188-202.
57. Taylor DM Antipsychotics and QT prolongation. Acta Psychiatr Scand 2003, 107:85-95.
58. Taylor D Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatr Scand 2008, 118:434-442.
59. Nasrallah H, Dewan N, Keck P Treating schizophrenia in patients with cancer. The clinical guide to pharmacotherapy for patients with co-occuring medical conditions 2005, University of Cincinnatti (USA), Cincinnatti.
60. van Erp NP, Gelderblom H, Guchelaar HJ Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009, 35:692-706.
61. Nemeroff CB, Devane CL, Pollock BG Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996, 153:311-320.
62. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010, 340:693.
63. Andersohn F, Willich SN Interaction of serotonin reuptake inhibitors with tamoxifen. BMJ 2010, 340:783.
64. Borus JF The other part of the elephant. Mental disorder screening in primary health care settings and physical disorder screening in psychiatric settings. Med Care 1987, 25:100-102.
65. Miovic M, Block S Psychiatric disorders in advanced cancer. Cancer 2007, 110:1665-1676.
66. Damjanovic A, Ivkovic M, Jasovic-Gasic M, Paunovic V Comorbidity of schizophrenia and cancer: clinical recommendations for treatment. Psychiatr Danub 2006, 18:55-60.
67. Baile W, DiMaggio J, Shapira D, Janofsky J The request for assistance in dying. The need for psychiatric consultation. Cancer 1993, 72:2786-2791.
68. Woods A, Willison K, Kington C, Gavin A Palliative care for people with severe persistent mental illness: a review of the literature. Can J Psychiatry 2008, 53:725-736.
69. Foti ME, Bartels SJ, Merriman MP, Fletcher KE, Van Citters AD Medical advance care planning for persons with serious mental illness. Psychiatr Serv 2005, 56:576-584.
70. Munday D, Petrova M, Dale J Exploring preferences for place of death with terminally ill patients: qualitative study of experiences of general practitioners and community nurses in England. BMJ 2009, 339:2391.
71. Howe E Ethical considerations when treating patients with schizophrenia. Psychiatry 2008, 5:59-64.
72. Owen GS, Richardson G, David AS, Szmukler G, Hayward P, Hotopf M Mental capacity to make decisions on treatment in people admitted to psychiatric hospitals: cross sectional study. BMJ 2008, 337:448.
73. Department of Health. UK Mental Capacity Act. London, 2005.
74. Kunkel EJ, Woods CM, Rodgers C, Myers RE Consultations for 'maladaptive denial of illness' in patients with cancer: psychiatric disorders that result in noncompliance. Psychooncology 1997, 6:139-149.
75. Schwartz CE, Steinmuller RI, Dubler N The medical psychiatrist as physician for the chronically mentally ill. Gen Hosp Psychiatry 1998, 20:52-61.
76. Butow P, Harrison JD, Choy ET, Young JM, Spillane A, Evans A Health professional and consumer views on involving breast cancer patients in the multidisciplinary discussion of their disease and treatment plan. Cancer 2007, 110:1937-1944.
77. Lane R, McLellan F, Santangelo J Personal account: a new feature from the patient's perspective. Lancet 2004, 363:262.
78. Sweeney A, Beresford P, Faulkner A, Nettle M, Rose D This is survivor research 2009, PPCS Books, Ross-on-Wye.
79. Sontag S Illness as a Metaphor 1978, Penguin, Harmondsworth.